{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-056191","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.321235+00:00","generated_at":"2026-06-01T01:24:56.286689+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Raphael Pharmaceutical increases authorized common shares to 50M (from 21M)","bullets":["Authorized common shares increased from 21,020,560 to 50,000,000 effective June 26, 2024.","Board approved the increase on May 9, 2024; majority shareholders approved on May 22, 2024.","Company filed Amended and Restated Articles of Incorporation with Nevada Secretary of State."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-056191","json":"https://secwatch.observer/filing/0001213900-24-056191.json","markdown":"https://secwatch.observer/filing/0001213900-24-056191.md","text":"https://secwatch.observer/filing/0001213900-24-056191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390024056191/0001213900-24-056191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390024056191/ea0208572-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:24:56.286689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}